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SUMMARY
X-linked adrenal hypoplasia congenita typically manifests as primary adrenal insufficiency in the 
newborn age and hypogonadotropic hypogonadism in males, being caused by mutations in NR0B1 
gene. We present the clinical and follow-up findings of two kindreds with NR0B1 mutations. The 
proband of kindred A had a diagnosis of primary adrenal insufficiency when he was a newborn. 
Family history was relevant for a maternal uncle death at the newborn age. Beyond 2 year-old ster-
oid measurements rendered undetectable and delayed bone age was noticed. Molecular analysis of 
NR0B1 gene revealed a previously unreported mutation (c.1084A>T), leading to a premature stop 
codon, p.Lys362*, in exon 1. His mother and sister were asymptomatic carriers. At 14 year-old he had 
3 mL of testicular volume and biochemical surveys (LH < 0.1 UI/L, total testosterone < 10 ng/dL) con-
cordant with hypogonadotrophic hypogonadism. Kindred B had two males diagnosed with adrenal 
insufficiency at the newborn age. By 3 year-old both siblings had undetectable androgen levels and 
delayed bone age. NR0B1 molecular analysis identified a nonsense mutation in both cases, c.243C>G; 
p.Tyr81*, in exon 1. Their mother and sister were asymptomatic carriers. At 14 year-old (Tanner stage 
1) hypothalamic-pituitary-gonadal axis evaluation in both males (LH < 0.1UI/L, total testosterone < 10 
ng/dL) confirmed hypogonadotropic hypogonadism. In conclusion, biochemical profiles, bone age 
and an X-linked inheritance led to suspicion of NR0B1 mutations. Two nonsense mutations were 
detected in both kindreds, one previously unreported (c.1084A>T; p.Lys362*). Mutation identification 
allowed the timely institution of testosterone in patients at puberty and an appropriate genetic coun-
selling for relatives. Arch Endocrinol Metab. 2015;59(2):181-5
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INTRODUCTION
X -linked adrenal hypoplasia congenita (AHC; OMIM: 300200) is a rare disorder characterized 
by the lack of the permanent adrenal cortical zone (1), 
representing 0,97% of all causes of primary adrenal 
insufficiency (PAI) under age 18 (2). It usually mani-
fests as severe PAI in a bimodal fashion (5-60 days and 
2-13 years) (3) and hypogonadotropic hypogonadism 
(HH) in males at the expected time of puberty (4). It 
is caused by mutations in NR0B1 (Nuclear Receptor 
subfamily 0, group B, member 1; also know as Dos-
age-sensitive sex reversal, adrenal hypoplasia congenita, 
critical region on chromosome X, gene 1, DAX-1), a 
gene encoding an orphan nuclear receptor expressed in 
hypothalamus, pituitary, adrenal gland and gonads, as 
well as in other tissues (5). 
Herein we present two kindreds with NR0B1 muta-
tions, one previously unreported, and a brief review of 
the literature regarding X-linked AHC. 
CLINICAL CASES
Kindred A. A newborn male presented to the Emer-
gency Department (ED) at 18 days of life with vomits, 
anorexia and generalized hypotony. He was born at 41 
weeks of an uneventful pregnancy. Family history was 
remarkable for a premature death of an uncle (4 days of 
life, unknown cause). Physical examination revealed de-
hidratation and hyperpigmentation of axilae, areola and 
scrotum. Biochemical findings of hypoglycaemia (63 
mg/dL) and altered electrolytes (Na+: 117 mEq/L; K+: 
7.9 mEq/L) prompted empirical treatment with gluco-
corticoids due to suspected PAI. Hormonal assays re-
vealed elevated ACTH and androstenedione (Table 1), 
and the patient was referred to our department with 
a diagnosis of congenital adrenal hyperplasia (CAH) 
based on non age-adjusted levels of 11-deoxycortisol 
(adult reference: < 1 ng/mL). However, follow-up ap-
pointments revealed a gradual and atypical decrease of 
androgen levels to below the analytic sensitivity of the 
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assays with mean doses of hydrocortisone of 19.5 mg/m2 
(Figure 1A). Delayed bone age (2 yo; chronologic age: 
2.9 yo) was also documented. Linking together, these 
surveys led to the hypothesis of a misdiagnosis of CAH. 
A short Synacthen® test also failed to rise 11-deoxycor-
tisol or 17-OHP levels (Table 2), excluding CAH and 
raising the suspicion for X-linked AHC. After approval 
by the local ethics committee and informed consent 
had been obtained from parents, molecular analysis 
of the NR0B1 gene was carried out, which revealed a 
c.1084A>T mutation leading to a premature stop co-
don (p.Lys362*) in exon 1 (Figure 2A). His mother 
and sister were asymptomatic carriers, whereas his ma-
ternal aunt had the wild type allele. This mutation, not 
previously described, gives rise to a premature stop co-
don, probably leading to a non-functional truncated 
protein.
From 6.8 to 13.9 yo his height curve crossed from 
-0.03SD to -1.79SD and testicular volume (3 mL) at 14 
yo confirmed the clinical diagnosis of delayed puberty. 
Gonadotropins (LH < 0.1 UI/L) and total testoste-
rone (TT) levels (< 10 ng/dL) were also prepubertal. 
Testosterone replacement therapy (100 mg/month, 
IM) was started and at 17.6 yo the patient achieved a 
height (167.3 cm, -1.35SD) close to his target height 
(173.5 cm). 
Two kindreds with X-linked AHC
Table 1. Probands of kindreds A and B: basal endocrinological surveys†
Kindred A B 
Age of the proband 19 days 6 months
Parameters Value [reference (6)]
17-OHP (ng/mL) 3.3 [1.6-9.6] 5 [0.2-3]
11-deoxycortisol (ng/mL) 28.9 [21.1-93.2] 3.9 [1.37-11]
Androstenedione (ng/mL) 7.2 [0.05-2.6] 1.45 [0.1-3]
Cortisol (mcg/dL) 8 [1.5-30.4] 23 [1.2-35.9]
Plasma renin activity (ug/L/h) * 59.9 [2.4-37]
ACTH (pg/mL) 156.8 [< 50] 878.2 [< 50]
† Glucocorticoid withdrawal therapy period: proband of kindred A – 0.5 days; proband of kindred 
B – 1.5 days.
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Figure 1. Serial basal measurements of steroids and ACTH: proband of kindred A over 24 months (A) and proband of kindred B over 48 months (B).
Table 2. Cosyntropin stimulation test† in probands of kindreds A and B
Parameters 11-deoxycortisol (ng/mL)
17-OHP  
(ng/mL)
Cortisol 
(mcg/dL)
Kindred (proband) A B A B A B
Basal < 1.5 0.4 < 0.1 4.9 < 1 23
30´ < 1.5 0.25 < 0.1 3.9 < 1 23
60´ < 1.5 0.4 < 0.1 2.2 < 1 22.3
† Glucocorticoid withdrawal therapy period: 1 day.
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Figure 2. NR0B1 sequencing results of the two probands and their 
mother’s.
Two kindreds with X-linked AHC
Kindred B. A Caucasian male presented to the ED 
at day 14th of life with failure to thrive (-12.5% of birth 
weight). He was the first of 4 children (3 males, 1 fema-
le) and was born after 38 weeks of a healthy pregnancy. 
No relevant family history was perceived. Hypoglycae-
mia (64 mg/dL), low sodium (121 mEq/L) and high 
potassium (8.8 mEq/L) led to a presumptive diagnosis 
of PAI, which was treated accordingly. At 6 months of 
age the patient was referred to our department with 
a diagnosis of CAH based on an elevated 17-OHP 
(Table 1), but a short Synacthen® test failed to further 
increase 17-OHP levels (Table 2). In addition, the an-
drogen levels in the follow-up appointments rendered 
easily undetectable with mean doses of hydrocortisone 
of 16.5 mg/m2 (Figure 1B). Delayed bone age (2.5 yo; 
chronologic age: 3 yo) was also noticed, reinforcing the 
need to seek for other causes of PAI. 
The third child of this family was a full term male 
who had a clinical diagnosis of PAI at 16 days of life. 
Hormonal surveys revealed elevated 17-OHP (16.8 
ng/mL, reference for age: 1.6-9.6) and a diagnosis of 
CAH was established before reference to our depart-
ment. During childhood, however, several admissions 
to the ED due to intercurrent illnesses revealed a con-
sistently elevated ACTH (1.133 pg/mL) with undetec-
table steroid levels (17-OHP < 0.1 ng/mL; androstene-
dione < 0.2 ng/mL; dehydroepiandrosterone-sulphate 
< 10 ug/dL). At this stage, clinical data of both siblings 
raised the suspicion of a X-linked mutation of NR0B1. 
After obtaining institutional ethics approval and written 
consent from their parents, molecular analysis allowed 
the identification of the nonsense mutation c.243C>G 
(p.Tyr81*) in exon 1 (Figure 2B), present in the two 
affected males. This mutation also gives rise to a pre-
mature stop codon and to a non-functional truncated 
protein. Their mother and sister were asymptomatic 
carriers. 
At the expected time of puberty the 2 affected 
males had growth velocities of 3.8 cm/year (-3.4SD, 
proband at 13.4 yo) and 1.99 cm/year (-4.89 SD, 
affected sibling at 13.6 yo) and testicular volumes of 
2 mL. Both HPG axis evaluations revealed concordant 
low basal LH (< 0.1 UI/L) and TT (< 10 ng/dL). 
After initiation of testosterone replacement therapy, a 
marked raise of growth velocity (proband at 15.3 yo: 
9.1 cm, 1.96SD; affected sibling at 14.6 yo: 8.7 cm, 
1.55SD) was noticed, leading to presently height statu-
res (target height: 170.5 cm) of 167 cm (proband, 18.3 
yo: -1.42SD) and 165.6 cm (affected brother, 15.2 yo: 
0.13SD).
DISCUSSION
Since the first description of NR0B1 mutations as the 
genetic aetiology of X-linked AHC (1), more than 100 
mutations have been reported in the literature. Most of 
them are nonsense or frameshift mutations that generate 
premature stop codons and truncated proteins (7-8). 
The evidence shows that NR0B1 acts mainly through 
a repressive modulation of NR5A1 (Nuclear Receptor 
subfamily 5, group A, member 1; also known as Ste-
roidogenic Factor 1, SF-1), a gene with an essential role 
in the development of both the hypothalamic-pituitary-
adrenocortical (HPA) and hypothalamic-pituitary-go-
nadal (HPG) axis. Although this modulation seems 
paradoxical, current models of adrenal gland develop-
ment suggest that NR5A1 acts on the differentiation of 
deep mature cortex layers (where NR0B1 is underex-
pressed), whereas in the more superficial cortical strata 
NR0B1 expression, along with NR5A1 and other mo-
lecular signals, maintains pluripotency of precursor cells 
and so the continuous external to internal development 
of the adrenal gland. The disruption of this molecular 
coordination would then impair its development (5). 
In HPG axis the mechanism by which NR0B1 gene 
disruption leads to HH is also not well clarified (5). 
To date, the evidence shows that mutations in NR0B1 
have negative effects at both hypothalamic and pituita-
ry levels, as shown in dynamic studies of HPG axis (9). 
At the gonadal level, targeted disruption of NR0B1 in 
mice leads to testis digenesis and to severely compro-
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
184 Arch Endocrinol Metab. 2015;59/2
mised spermatogenesis, showing its importance in the 
development of the gonads (5).
Our cases reflect the classical and most severe form 
of X-linked AHC. At diagnosis, the presentation is in-
distinguishable from the more common CAH, and it is 
frequent to misdiagnose patients as having this disor-
der until evidence of delayed puberty, when X-linked 
AHC is usually considered (5,10). The suspicion of 
an NR0B1 mutation in the kindreds herein reported 
was based on a combination of an apparent X-linked 
pattern of inheritance, decreasing androgen levels over 
the first years of life and delayed bone age. This set of 
clinical data was extremely useful in excluding the diag-
nosis of CAH, as this latter pathologic condition is cha-
racterized by an autosomal recessive pattern of trans-
mission, elevated androgen levels and advanced bone 
age (11). Nevertheless, clinicians should be aware of 
the possible pitfalls during the diagnostic approach of 
X-linked AHC. Firstly, besides the typical presentation 
of this disorder, it is also characterized by a significant 
phenotypic variability. Later childhood presentations 
(e.g., 7-8 yo) or transitorily compensated forms (from 2 
to 12 years) can coexist within the same family with the 
more severe neonatal phenotypes (3,5,10,12). Additio-
nally, late-onset (20-28 yo) PAI (13-15), female pre-
sentations (16-18) or only mineralocorticoid deficiency 
(19) have also been reported. Thus, it is of paramount 
importance to be aware that NR0B1 mutations can 
manifest with these atypical phenotypes, which should 
not preclude the diagnosis. Interestingly, although ge-
notype-phenotype correlations are characteristically ab-
sent in X-linked AHC, mutations in NR0B1 gene that 
maintains a partial repressor activity are usually con-
sistent with more mild phenotypes, as a compensated 
adrenal insufficiency until adulthood (13,15). 
Secondly, as illustrated in our patients, elevated ste-
roid levels at presentation can also lead to a misdiagno-
sis of CAH. Normal to high levels (e.g. 11-deoxicor-
tisol) of androgens and cortisol can be present in the 
first months of life (usually 6 months postnatal) as a 
hallmark of persistent fetocortex activity (5). However, 
as shown in both kindreds, cosyntropin administration 
usually fails to significantly raise steroid precursors or 
cortisol (20) and serial basal measurements over time 
typically reveal a progressive decrease in androgens to 
undetectable levels (4), given the natural involution of 
foetal cortex. Additionally, appropriate assays should 
be selected to avoid falsely elevated hormone levels, as 
cross-reactions with other abundant fetocortical steroi-
ds can occur with some of the available measurement 
methods (4). 
In the differential diagnosis of X-linked AHC, besi-
des CAH, some authors have reported that, when other 
disorders have been excluded in a male infant (metabo-
lic – Zellweger or Wolman – syndromes, adrenal hae-
morrhage) or in an older child (autoimmune disease, 
X-linked adrenoleukodistrophy, Triple A syndrome, 
infection), it can be valuable to test for NR0B1 muta-
tions, where its prevalence can reach to 58% (3). 
Making a diagnosis of a NR0B1 mutation has se-
veral important implications. First, genetic testing for 
NR0B1 mutations can be offered to potential carrier 
mothers and their female offspring before fertile ages, 
as early diagnosis and neonatal institution of salvage 
therapy in affected male newborns can prevent signifi-
cant morbidity or death (12). Second, the clinician can 
suitably inform parents that HH will almost certainly 
arise in their affected child and discuss with them the 
available treatments and the appropriate age at which 
they should be initiated (21-22). Taking our kindreds 
as an example, the early diagnosis of X-linked AHC 
allowed the timely institution of testosterone when de-
layed puberty ensued, leading to improved final hei-
ghts. Third, it also allows clarifying parent’s expecta-
tions related with fertility of their male offspring, which 
in X-linked AHC almost always carries a poor progno-
sis. These patients usually have severe oligospermia and 
disorganized seminiferous structures at histopathology, 
and attempts to achieve fertility have often proved un-
successful (5,14,23). Nevertheless, a previous report 
has shown hopeful results with testicular sperm extrac-
tion and intracytoplasmatic injection treatments (24).
In summary, we reported two kindreds with 
X-linked AHC, one of them with a previously unre-
ported NR0B1 mutation. We also highlighted some 
challenging aspects of its differential diagnosis, as well 
as the importance of establishing a correct diagnosis for 
a suitable genetic counselling and appropriate manage-
ment of affected members.
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